期刊
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
卷 26, 期 3, 页码 266-277出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jagp.2017.10.010
关键词
Bioavailable curcumin; normal aging; memory; cognition; positron emission tomography
资金
- Ahmanson Foundation
- McComb Foundation
- McMahan Foundation
- Bob and Marion Wilson
- Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research
- Plott Professorship
- Parlow-Solomon Professorship
- National Institutes of Health [P01-AG025831, AG13308, P50 AG 16570, MH/AG58156, MH52453, AG10123, M01-RR00865]
- U.S. Department of Energy [DE-FC03-87-ER60615]
- General Clinical Research Centers Program
- Allergan
- Argentum
- Axovant
- Cogniciti
- Forum Pharmaceuticals
- Herbalife
- Janssen
- Lundbeck
- Lilly
- Novartis
- Otsuka
- Pfizer
- McCormick Science Institute
Objective: Because curcumin's anti-inflammatory properties may protect the brain from neurodegeneration, we studied its effect on memory in non-demented adults and explored its impact on brain amyloid and tau accumulation using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene) malononitrile positron emission tomography (FDDNP-PET). Methods: Forty subjects (age 51-84 years) were randomized to a bioavailable form of curcumin (Theracurmin (R) containing 90 mg of curcumin twice daily [N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A) was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo) were determined in amygdala, hypothalamus, medial and lateral temporal, posterior cingulate, parietal, frontal, and motor (reference) regions. Mixed effects general linear models controlling for age and education, and effect sizes (ES; Cohen's d) were estimated. Results: SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = -0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = -0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02). Conclusions: Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The FDDNP-PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据